Irving-based Caris Life Sciences is Expanding its Footprint Here With a New Corporate Park

The Caris Life Sciences Corporate Park in Irving will increase R&D capabilities with a state-of-the-art precision medicine laboratory, create more than 500 jobs in the region, and help Caris continue to "reinvent cancer care."

Caris Life Sciences is growing its presence in North Texas. The Irving-headquartered biotech innovator today announced it’s developing a new corporate park, creating more than 500 job opportunities in the process.

Caris is a leader in molecular science that’s focused on precision medicine. For instance, Caris uses molecular information to personalize therapy for cancer patients. It’s already changed the way patients are diagnosed and treated, and even acquired Pharmatech Inc. back in May to redefine cancer treatment by pairing each patient with the right clinical trial, regardless of their location, in as little as 10 days.

The Caris Life Sciences Corporate Park will also be located in Irving. There, employees will be tasked with increasing research and development capabilities in the facility’s 115,000-square-foot R&D laboratory and office space.

And, Caris said team members will continue to improve the lives of cancer patients through its molecular profiling offerings, while working to expand “blood-based diagnostic assays” and “blood-based molecular profiling.”

The suite of proprietary molecular profiling offerings are intended to help physicians make more precise and personalized treatment decisions. By assessing DNA, RNA, and proteins, the offerings show a molecular blueprint that could impact cancer patients.

David D. Halbert, Caris’ chairman and CEO, said the new facility will enhance the company’s ability to assist physicians and drug developers in improving and saving lives. 

“Caris is working to reinvent cancer care,” he said.  “We have made investments in science, expertise, infrastructure and proprietary technologies that cannot be rivaled, and we are combining these in unique ways to create comprehensive offerings for clinicians and researchers that others cannot.”

David Halbert is Caris’ chairman and CEO. [Photo: Courtesy Caris Life Sciences]

The new facility is already being developed, with the first of the three phases expected to be finished early next year. The first phase will feature blood-based diagnostics laboratories, R&D, and corporate office space, while the second and third will bring additional laboratories for Caris’ tumor profiling offering.

Caris currently employs around 700 people—from MDs and PhDs to research scientists and pathologists—which is a number that has more than doubled in a little more than a year.

With the addition of the Corporate Park in Irving, Caris will have a total footprint of more than 300,000 square feet. That also includes: a 135,000-square-foot complex in Phoenix, a 7,000-square-foot pharmatech operation in Denver, and international offices in Basel, Switzerland. 

“We are pioneers in molecular science with a long history of driving revolutionary change and innovation in precision medicine,” Michael Halbert, SVP of Human Resources, said in a statement. “Caris continues to thrive because of this strategic vision and our expansion will ensure that every patient has access to the most advanced cancer care.”

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T